Trial Profile
Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population (ProPositive Study)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2021
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal group B infections
- Focus Pharmacodynamics
- Acronyms ProPositive
- 08 Apr 2019 Status changed from not yet recruiting to recruiting.
- 15 Jan 2019 Planned initiation date changed from 1 Sep 2018 to 1 Feb 2019.
- 28 Sep 2018 New trial record